2013 – Astex

2013 ASH: First Clinical Results of a randomized Phase 2 study of SGI-110 in adult patients with AML

25 November 2013/in 2013, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2013 ASH: First Clinical Results of a randomized Phase 2 study of SGI-110 in adult patients with AML

2013 ASH: Determinants of Demethylation and Clinical Response in AML patients treated with SGI-110

25 November 2013/in 2013, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2013 ASH: Determinants of Demethylation and Clinical Response in AML patients treated with SGI-110

2013 ASH: DNA Demethylation Activity over time and safety regimens of SGI-110 in r/r MDS and AML pts

20 November 2013/in 2013, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2013 ASH: DNA Demethylation Activity over time and safety regimens of SGI-110 in r/r MDS and AML pts

2013 Cell Symposia: Cancer Epigenomics. Anti-tumour Activity of SGI-110, a Novel Hypomethylating

15 November 2013/in 2013, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2013 Cell Symposia: Cancer Epigenomics. Anti-tumour Activity of SGI-110, a Novel Hypomethylating

2013 ECCO: Study of correlation baseline biomarkers and DNA demethylation to clin response of SGI-11

10 November 2013/in 2013, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2013 ECCO: Study of correlation baseline biomarkers and DNA demethylation to clin response of SGI-11

2013 AACR: SGI-110 induces Cancer Germline (CG) antigen expression in Acute Myeloid Leukemia cells

9 November 2013/in 2013, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2013 AACR: SGI-110 induces Cancer Germline (CG) antigen expression in Acute Myeloid Leukemia cells

2013 EORTC: Epigenetic priming with SGI-110 improved antitumor activity of CTLA-4 blockade

8 November 2013/in 2013, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2013 EORTC: Epigenetic priming with SGI-110 improved antitumor activity of CTLA-4 blockade

2013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine

7 November 2013/in 2013, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine

2013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer

6 November 2013/in 2013, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer

2013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent

4 November 2013/in 2013, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent